Delivery Order W911SR24D0001-W911SR24F0016
Award Date 1/22/24
Potential Completion Date 9/30/25
Potential Value $42M
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Available for Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lansing, MI 48906, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...
- This federal contract award is for BAXTER CELL HARVEST services in year 6 of the contract, awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense. The contract has a ceiling value of $38,250,000.00 and was awarded on September 30, 2016, with an ultimate completion date of August 31, 2018. It is a Firm Fixed Price delivery order contract. Emergent Biodefense is a for-profit manufacturer of...
- The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response awarded a $79,947,200.00 Firm Fixed Price contract to Elusys Therapeutics Inc. for the manufacture and vendor managed inventory of Anthim (obiltoxaximab) 600mg/6ml for Injection, an FDA-approved anthrax antitoxin. The contract has a period of performance from August 6, 2021 through September 14, 2024, and includes options for additional manufacturing and delivery of finished drug...
- <p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>
- <p>The Defense Logistics Agency issued a $4,631.53 delivery order to Amerisourcebergen Drug Corp on March 17, 2026, for ENGERIX-B 20 MCG/ML vaccine supply.</p> <p>The order is issued under the company's parent IDC with DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2026. Place of performance is Conshohocken, PA. The order carries a firm fixed price and an ultimate completion date of March 18, 2026. No set-aside applied to this award.</p>
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution and supply company. The contract is a Delivery Order with a Firm Fixed Price of $1,243.99, for the supply of the vaccine product ENGERIX-B 20 MCG/ML VIALML. The contract has a completion date of April 30, 2024 and was awarded on April 29, 2024. This contract is not set aside for any specific business category. Amerisourcebergen Drug Corp, through its...
- The Defense Logistics Agency awarded a $5,210.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 16, 2026, for ENGERIX-B 20 MCG/ML Vial, a hepatitis B vaccine product. The contract is non-set-aside and was competitively awarded, with performance scheduled for completion by January 20, 2026, at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,267.01 to AmerisourceBergen Drug Corp on September 12, 2025, for ENGERIX-B 20 MCG/ML Vial vaccines. This competitive contract, which requires completion by September 15, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and is well-positioned to fulfill this...
- The Defense Logistics Agency issued a $28,786.80 delivery order to Amerisourcebergen Drug Corp on April 14, 2026, for ENGERIX-B 20 MCG/ML vaccine supply. The order is issued under the parent DLA Troop Support Medical IDC (valued at up to $999,999,999.00 through December 2026), which provides comprehensive global pharmaceutical and medical supply support to military healthcare programs. Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of...
- This delivery order, awarded on January 6, 2026, procures ENGERIX-B 20 micrograms per milliliter vaccine syringes valued at $1,533.22 for the Defense Logistics Agency (DLA). The award was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, with performance taking place at the same location. The contract was competitively awarded with no set-aside designation and utilizes firm fixed-price pricing, with an ultimate completion...